Julie R. Brahmer, MD, associate professor of oncology and co-director of the Upper Aerodigestive Department at the Bloomberg Kimmel Institute for Cancer Immunotherapy, John Hopkins Medicine, discusses the change in standard of care for patients with stage III non–small cell lung cancer. Durvalumab was recently approved by the FDA as a consolidation therapy for patients with stage III locally-advanced, unresectable NSCLC who had not progressed following standard chemoradiotherapy.
Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses results from the phase II open-label, single-arm QUADRA study evaluating niraparib in patients with relapsed ovarian cancer who have received ≥3 prior chemotherapy regimens during the 2018 ASCO Annual Meeting.
Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses overall survival results from the phase III COLUMBUS trial investigating encorafenib plus binimetinib versus vemurafenib (Zelboraf) or encorafenib in BRAF-mutant melanoma during the 2018 ASCO Annual Meeting.
Shilpa Gupta, MD, assistant professor of Medicine in the Hematology, Oncology, and Transplantation Division, University of Minnesota, discusses phase Ib and phase II studies of pembrolizumab (Keytruda) with bevacizumab (Avastin) for the treatment of metastatic renal cell carcinoma during the 2018 ASCO Annual Meeting.
Benjamin G. Neel, MD, PhD, director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone, discusses how his institution has changed vastly over the last few years, with an increasing number of clinical trials available for patients with lung cancer and other cancers. Clinical trials are often the best option for cancers where the outcomes with conventional treatments may be uncertain, Neel says.
Jeffrey S. Weber, MD, PhD, deputy director of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the adverse events commonly associated with the combination of dabrafenib and trametinib in the adjuvant setting for patients with BRAF V600E– or V600K–positive stage III melanoma.
Optimizing Targeted Therapy in IgVH-Unmutated CLL
Toni K. Choueiri, MD, a medical oncologist at Dana-Farber Cancer Institute, discusses how clinical trials can help improve cancer treatments for patients with metastatic renal cell carcinoma, a largely incurable and lethal disease. He also shares recent statistics on the low clinical enrollment numbers as well as how many could potentially be enrolling for newer treatments.
Steven E. Coutre, MD, professor at the Stanford University Medical Center, discusses the importance of molecular profiling in hematologic diseases, including acute lymphoblastic leukemia.
Optimizing the Management of HER2+ Inflammatory Breast Cancer
Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the significance of his findings when combining an anti-CTLA-4 and anti-PD-1 in patients with multiple myeloma. He sought out to find whether these 2 drugs could be combined safely after an autologous stem cell transplant.
Improving the Treatment of Locally Advanced Pancreatic Cancer
Sumanta K. Pal, MD, associate professor of the Department of Medical Oncology and Experimental Therapeutics at City of Hope, discusses the data he considers when treating patients with metastatic urothelial carcinoma.
Brian T. Hill, MD, PhD, director of Lymphoid Malignancies at the Cleveland Clinic, discusses current combinations being investigated for the treatment of patients with mantle cell lymphoma.